PharmaNet Development Group Announces Strategic Alliance with Analytica International

Business Wire, March 19, 2007

PRINCETON, N.J. & NEW YORK -- PharmaNet Development Group, Inc. (NASDAQ: PDGI) and Analytica International, Inc., a wholly-owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI), today announced that they have entered into a strategic alliance that will allow the companies to provide a broader range of clinical development and commercialization expertise to their respective clients.

PharmaNet Development Group, Inc. is a leading provider of clinical-development services solutions including early and late stage clinical trials and related services. Analytica International, Inc. is a healthcare research consultancy that provides outcomes research, pricing and reimbursement analysis for global pharmaceutical, biotechnology, and medical device companies.

Increasingly, clinical trial sponsors and medical professionals are incorporating health economic and patient reported outcomes in clinical trials to better understand the value of a therapeutic candidate. Outcomes research can help valuate the clinical, economic, and humanistic attributes of a product for a manufacturer. Accordingly, payers can use outcomes research tools to assess the 'real-world' cost-effectiveness of products being introduced to their formularies. The application of outcomes research is of particular value in the area of chronic diseases, where a cure may not be the only objective, and can provide information that helps patients make choices that may improve their quality-of-life.

"Analytica International's outcomes research will enhance PharmaNet's clinical trial services offering when health outcomes are part of the sponsor's large scale, Phase III-IV trial protocol," commented Jeffrey P. McMullen, President and Chief Executive Officer, PharmaNet Development Group, Inc.

"Our global biopharmaceutical clientele are looking for an integrated approach to designing and implementing clinical trials that incorporate outcomes research endpoints to maximize the value proposition of their products," commented Dr. John Doyle, President and Chief Operating Officer, Analytica International, Inc.

"PharmaNet is a highly regarded name among global CROs. We feel that together PharmaNet and Analytica can provide our clients exceptional service," Dr. Steven Arikian, Chairman and Chief Executive Officer, Analytica International continued. "We are excited by this opportunity to offer a more complete portfolio of services to our clients."

About PharmaNet Development Group, Inc.

PharmaNet Development Group, a global drug development company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug, and medical device industries. The Company offers clinical-development solutions including early and late stage consulting services, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2,200 employees and more than 35 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit their website at www.pharmanet.com.

About Analytica International, Inc.

Analytica International is a healthcare consulting company that works closely with manufacturers, physicians, and payers to guide drug development and optimal patient care. The Company is dedicated to providing innovative healthcare intelligence on the economics and outcomes of disease states, drug therapies, medical devices, and biotechnologies. Analytica integrates outcomes research, pricing, and reimbursement advisory services to offer our biopharmaceutical and medical device clients value-maximizing strategies for optimal return on investment. The company is based in New York, New York and in Lorrach, Germany. Analytica is a wholly-owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI). For more information, please visit their website at www.analyticaintl.com.

About Accentia Biopharmaceuticals, Inc.

Accentia Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of late-stage innovative clinical products, especially for already-approved drugs in new formulations and/or new indications that are patent-protected and which represent new therapeutics with greater clinical and economic value. Accentia has a pipeline of products in late-stage clinical development. The company's lead respiratory product candidate is SinuNase(TM), which is under clinical development to treat chronic sinusitis (rhinosinusitis). SinuNase is a novel application and formulation of a known anti-fungal exclusively licensed from the Mayo Foundation for Medical Education and Research. The product has been Fast Tracked by the FDA and the Company has commenced a Phase 3 clinical trial. The Company's other lead product is BiovaxID(TM), a patient-specific anti-cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma. BiovaxID, which is being developed by Accentia's subsidiary, Biovest International, Inc., (OTCBB: BVTI), is currently in a Fast-Tracked Phase 3 clinical trial. The Company is also proposing to enter Phase 3 clinical trials for Multiple Sclerosis using Revimmune[TM], which uses an approved drug in an exclusively licensed method of therapy to "reboot" a patient's immune system. Revimmune was developed at the Johns Hopkins School of Medicine for the elimination of autoimmunity, and Accentia has acquired the exclusive worldwide rights for all autoimmune diseases. For further information, please visit www.accentia.net.